Author(s)

Edgar G. Valdivia Lara¹, Andrés Ángeles Aldana¹, Jesica I. Ángeles Solis², Patricia Miranda Castro³, Juan C. Del Río García⁴, Guillermo Valdivia Anda¹

¹Laboratory of Microbial Pathogenicity, Multidisciplinary Research Unit, Faculty of Higher Education Cuautitlán, National Autonomous University of Mexico, Cuautitlán Izcalli, Mexico.
²Laboratory DIVETTM, Cuautitlan Izcalli, Mexico.
³Biotechnology Laboratory, UNAM, Cuautitlan Izcalli, Mexico.
⁴Laboratory of Mycotoxins, Multidisciplinary Research Unit, Faculty of Higher Education Cuautitlan, National Autonomous University of Mexico, Cuautitlan Izcalli, Mexico.

Neutrophils are the most important circulating phagocytes. Circulating mono-cytes and precursors of tissue macrophages also have the ability to phagocytize. Pidotimod (ADIMOD^TM) exerts immunostimulatory and immunoregulatory effects through the stimulation and regulation of cellular immune responses by lymphocytes Canine herpesvirus (CHV) mainly affect puppies between the first and second weeks of age, causing high morbidity in the litter. To date, there is only one commercial vaccine in Europe to prevent disease. In this work, inactivated CHV cultures were inoculated in rabbits, adsorbed and not adsorbed to chitosan nanoparticles. Phagocytosis in the presence or absence of specific antibodies was measured. Response of virus neutralizing antibodies was also evaluated. Adimod^TM enhanced the nonspecific and specific phagocytotic response. The association of the virus to the nanoparticles increased the phagocytic ability of blood cells; however, Adimod^TM alone had a greater effect on phagocytic activity and generated a stronger immune response that corresponded to the increased phagocytosis (p < 0.05). Moreover, the level of neutralizing antibodies was higher and increased more rapidly when Adimod^TM was used.

Phagocytosis, Canine Herpesvirus, Pidotimod Stimulation

Lara, E. , Aldana, A. , Solis, J. , Castro, P. , García, J. and Anda, G. (2017) Stimulation of Phagocytosis and Production of Antibodies against Canine Herpesvirus Type 1 by Pidotimod (Adimod^TM). Open Journal of Veterinary Medicine, 7, 38-47. doi: 10.4236/ojvm.2017.74005.